AVIR

Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals, Inc. (AVIR) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Growth (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.0
EV / EBITDA -0.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -22.0%
Price Return 12M 34.6%
Catalyst Signal 0.00
Market Cap $330.9M
TTM Revenue N/A
Price / Sales N/A
ROE -63.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C (2.2) C (2.4) C+ (2.8) C+ (2.6) C (2.5)
2026-11-10 C+ (2.5) C (2.3) C (2.4) B- (2.9) C+ (2.6) C+ (2.5)
2026-11-03 C+ (2.5) C (2.2) C (2.4) B- (2.9) C+ (2.7) C+ (2.5)
2026-10-27 C+ (2.5) C (2.2) C+ (2.6) C+ (2.8) C+ (2.6) C+ (2.6)
2026-10-20 C+ (2.5) C (2.2) C+ (2.6) C+ (2.7) C+ (2.6) C+ (2.5)
Page 1 of 5